Clinical Insights: September 14, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Sotyktu™ (deucravacitinib) Tablets – New Drug Approval – September 9, 2022 – Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class,…
Clinical Insights: September 7, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Konvomep™ (omeprazole and sodium bicarbonate) Powder for Oral Suspension – New Drug Approval – September 2, 2022 – Azurity Pharmaceuticals, Inc., a pharmaceutical company focused on developing innovative dose-forms…
Clinical Insights: August 31, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Pemazyre® (pemigatinib) – New Drug Approval – August 29, 2022 – The Food and Drug Administration approved pemigatinib (Pemazyre®, Incyte Corporation) for adults with relapsed or refractory myeloid/lymphoid neoplasms…
Clinical Insights: August 24, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Auvelity™ (dextromethorphan and bupropion) Extended-Release Tablets – New Drug Approval – August 19, 2022 – Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management…
Clinical Insights: August 17, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Tabrecta® (capmatinib) Tablets – New Expanded Label – August 10, 2022 – The Food and Drug Administration granted regular approval to capmatinib (Tabrecta®,…
RxStrategies to Attend the 2022 CHI & EXPO
Connect with Rhodie Smith during the National Association of Community Health Centers 2022 Community Health Institute (CHI) & EXPO, August 28-30. This event is a great opportunity for industry leaders to connect and share insights. Connect with RxStrategies during the event: Make sure to visit Booth #1015 to learn more about our 340B solutions | Floor plan…
Clinical Insights: August 10, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Kyzatrex™ (testosterone undecanoate) Capsules – New Drug Approval – August 2, 2022 – Marius Pharmaceuticals, a patient-centric healthcare company, announced the approval of Kyzatrex™ (testosterone undecanoate) by the U.S….
Clinical Insights: July 27, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage July 26, 2022 Daptomycin Injection (Discontinuation) Doxepin Hydrochloride Oral Solution (Discontinuation) Gentamicin Sulfate Injection (Currently in Shortage)…
Clinical Insights: July 20, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Zonisade™ (zonisamide oral suspension) – New Drug Approval – July 18, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs…
Meet Us at the 340B Coalition Summer Conference!
Our team members are looking forward to connecting with industry leaders at the upcoming 340B Coalition Summer Conference, August 1-3. RxStrategies is a proud Pinnacle Partner. Connect with our experts during the conference: Schedule an appointment with one of our team members. Schedule a platform demo. Visit RxStrategies booth: #409 | Floor plan link Monday, 8/1: 7:00am…
Clinical Insights: July 13, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Comirnaty® (COVID-19 Vaccine, mRNA) Injection – New Label Expansion – July 8, 2022 – Pfizer Inc. and BioNTech SE announced the U.S. Food…
Clinical Insights: July 6, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Qsymia® (phentermine and topiramate) Extended-Release Capsules – New Label Expansion – June 24, 2022 – The U.S. Food and Drug Administration has approved…